The efficacy of ranibizumab treatment in clinical practice in patients with the wet form of age-related macular degeneration. The results of the Czech National Registry

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F15%3A00084535" target="_blank" >RIV/00216224:14110/15:00084535 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11150/15:10320123 RIV/61989592:15110/15:33157937 RIV/65269705:_____/15:00063565 RIV/00179906:_____/15:10320123 RIV/00098892:_____/15:#0000967

Výsledek na webu

<a href="http://dx.doi.org/10.5507/bp.2015.017" target="_blank" >http://dx.doi.org/10.5507/bp.2015.017</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.5507/bp.2015.017" target="_blank" >10.5507/bp.2015.017</a>

Jazyk výsledku

angličtina

Název v původním jazyce

The efficacy of ranibizumab treatment in clinical practice in patients with the wet form of age-related macular degeneration. The results of the Czech National Registry

Popis výsledku v původním jazyce

Aims. The aim of this communication was to evaluate ranibizumab in the treatment of wet age-related macular degeneration. Methods. Anonymised data on treatment efficacy and safety were consecutively entered into the Czech national database. From 01/09/2008 to 25/10/2011, 671 patients/685 eyes treated with ranibizumab monotherapy were entered in the registry. 454 ranibizumab treated eyes and 444 patients were monitored for 12-months. The dependent variable used to monitor disease progression and treatment results was change in visual acuity in the ETDRS (Early Treatment Diabetic Retinopathy Study) chart over time. Results. After 12 months of treatment, a loss of &lt; 15 letters in the ETDRS chart was found in 81.5% of eyes treated with ranibizumab. A gain of &gt;/= 15 letters was found in 9.7% of eyes on ranibizumab.

Název v anglickém jazyce

The efficacy of ranibizumab treatment in clinical practice in patients with the wet form of age-related macular degeneration. The results of the Czech National Registry

Popis výsledku anglicky

Aims. The aim of this communication was to evaluate ranibizumab in the treatment of wet age-related macular degeneration. Methods. Anonymised data on treatment efficacy and safety were consecutively entered into the Czech national database. From 01/09/2008 to 25/10/2011, 671 patients/685 eyes treated with ranibizumab monotherapy were entered in the registry. 454 ranibizumab treated eyes and 444 patients were monitored for 12-months. The dependent variable used to monitor disease progression and treatment results was change in visual acuity in the ETDRS (Early Treatment Diabetic Retinopathy Study) chart over time. Results. After 12 months of treatment, a loss of &lt; 15 letters in the ETDRS chart was found in 81.5% of eyes treated with ranibizumab. A gain of &gt;/= 15 letters was found in 9.7% of eyes on ranibizumab.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FF - ORL, oftalmologie, stomatologie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Biomedical Papers of the Faculty of Medicine of Palacký University

ISSN

1213-8118

e-ISSN

—

Svazek periodika

159

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

CZ - Česká republika

Počet stran výsledku

6

Strana od-do

407-412

Kód UT WoS článku

000364948100012

EID výsledku v databázi Scopus

—